Project Grant R01NS151858
- The National Institute of Neurological Disorders and Stroke awarded Case Western Reserve University $3,778,614 on August 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop and validate transient selective neural inhibition via photobiomodulation (TSNIP) for chronic knee pain treatment. The research integrates optimized TSNIP parameters into the COSMIIC modular platform—an FDA-qualified system already proven safe for electrical stimulation and sensing in...
- The National Institute of Neurological Disorders and Stroke awarded The Johns Hopkins University $580,924 on April 17, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to develop and validate ionic direct current stimulation as a neuromodulation tool for modulating neural population gain in cortical circuits. The research addresses a precision gap in existing neuromodulation technologies by developing computational models and...
- The National Institute of Neurological Disorders and Stroke awarded The Leland Stanford Junior University $423,500 on June 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to dissociate neural representations of pain and salience using intracranial human brain recordings. The research will obtain intracranial electroencephalography (iEEG) measurements in 20 neurosurgical patients as they perform thermal pain and auditory...
- The National Institute of Neurological Disorders and Stroke awarded the Regents of the University of Minnesota a cooperative agreement valued at $769,903 on August 1, 2026, to conduct a feasibility and pilot trial of a novel invasive brain stimulation approach for chronic neuropathic pain. The study combines precision functional mapping and individualized neurostimulation targeting the somato-cognitive action network and cingulo-opercular network—two key circuits in pain processing—to address...
- The National Institute of Neurological Disorders and Stroke, part of the Department of Health and Human Services National Institutes of Health, awarded $150,342 to the University of Washington on September 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The award funds investigation of how long-term, closed-loop, epidural spinal cord stimulation affects neuropathic pain symptoms in rats with cervical spinal cord injury. The...
- The National Institute of Neurological Disorders and Stroke (NINDS), part of the Department of Health and Human Services National Institutes of Health, awarded $619,189 to Massachusetts Institute of Technology on August 19, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to establish a bioelectronics-integrated mesoscale organ-on-a-chip platform for neuromuscular disease modeling. MIT will develop a limb-on-a-chip platform that...
- Federal Grant Award Summary The University of Iowa received a $427,625 Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, effective July 4, 2025, through June 30, 2027. This research project investigates the protective roles of the lithium-inducible SLC6 transporter in lithium's adverse effects using Drosophila genetics and physiology. The research...
- The National Institute of Neurological Disorders and Stroke (part of the Department of Health and Human Services National Institutes of Health) awarded Oregon Health & Science University $5.363 million on August 18, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to optimize spinal cord stimulation parameters for pain and itch management. The research investigates how epidural spinal cord stimulation engages dorsal horn circuits, specifically targeting neuropeptide Y...
- The National Institute of Neurological Disorders and Stroke awarded Massachusetts General Hospital $1.130557 million on August 20, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop a non-viral lipid nanoparticle-delivered gene therapy for acute pain treatment as an alternative to opioids. The project focuses on creating a focal-delivery, non-opioid therapeutic targeting postsurgical pain as the primary indication, with secondary applications to acute exacerbations...
- The National Institute of Neurological Disorders and Stroke awarded Washington University in St. Louis $493,332 on August 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to develop a surface electroneurography device for in-office assessment of peripheral nerve recovery. Washington University partnered with Biocircuit Technologies to design a diagnostic system addressing limitations in current peripheral nerve injury...
The National Institute of Neurological Disorders and Stroke awarded The University of Chicago $677,636 on August 15, 2026, to develop programmable lithium-ion delivery devices for motor-sparing neuropathic pain therapy under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The project introduces a lithium-delivering bioelectronic platform with AI-enabled closed-loop control that provides programmable, localized, and reversible conduction block for neuropathic pain. The core innovation repurposes lithium iron phosphate (LFP), a crystalline mineral cathode from energy storage, as a biocompatible and electrochemically stable source of lithium ions for neuromodulation. Unlike systemic lithium therapy or electrical stimulators, this approach achieves epineurial, spatially confined lithium release with high faradaic efficiency, tunable dosing, and chronic stability. Integrated with wearable sensors and edge-AI algorithms, the system enables real-time detection of pain-linked signatures and adaptive lithium release. Research is organized into four integrated aims. Aim 1 synthesizes LFP nano- and microparticles and fabricates flexible cuff and injectable electrodes using photolithography, with morphology tuning and kirigami-inspired geometries to enhance lithium diffusion and conformity. Aim 2 evaluates device biocompatibility and bio-stability through neuronal cultures, iPSC-derived networks, organotypic explants, and staged in vivo studies in spared-nerve-injury mice and peroneal nerve injury sheep. Aim 3 and additional objectives are described in the project summary. Work is performed in Chicago, Illinois. The period of performance extends through May 31, 2031.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $677.6k | 8/14/26 |